Alkermes Public Limited Company (ALKS)

Alkermes completed the acquisition of Avadel Pharmaceuticals in February 2026, integrating LUMRYZ. The FDA granted Breakthrough Therapy Designation to Alixorexton for Narcolepsy Type 1 in January 2026, with Phase 3 trials expected to commence soon. Alkermes reported its Q4 and full-year 2025 financial results on February 25, 2026, with an adjusted EPS of $0.29, missing the analyst forecast of $0.41. News of CEO Richard Pops' retirement in mid-2026 influenced investor sentiment. The expiration of royalties on U.S. net sales of INVEGA SUSTENNA in August 2024 significantly impacted the company's 2025 revenues. As of February 26, 2026, Alkermes' shares had gained 7.1% over the past six months, but as of March 2, 2026, the share price had declined by 11.35% over the past year.

While a detailed breakdown of demand seasonality for each of Alkermes' products is not extensively detailed in public records, there are indications of some quarterly variations. The company's Q4 2024 earnings report mentioned "year-end inventory fluctuations and gross-to-net favorability, primarily driven by Medicaid utilization adjustments" for Vivitrol, Aristada, and Lybalvi. The Q1 2026 guidance for royalty and manufacturing revenues reflects "typical Q1 end-market demand patterns." Despite these mentions of quarterly dynamics and inventory fluctuations, the company's earnings calls frequently highlight "strong end market demand" and "underlying demand remained solid" for its proprietary products like Vivitrol, Aristada, and Lybalvi, suggesting consistent demand throughout the year, albeit with some expected quarterly adjustments related to inventory and gross-to-net factors.

Alkermes Plc is a global biopharmaceutical company focused on developing medicines for central nervous system disorders and oncology, with a focus on psychiatric and neurological disorders. Key proprietary commercial products include Lybalvi for schizophrenia and bipolar I disorder, Aristada for schizophrenia, Vivitrol for alcohol and opioid dependence, and LUMRYZ for narcolepsy. Partnered products include Vumerity for multiple sclerosis, Risperdal Consta for schizophrenia and bipolar I disorder, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, and Invega Hafyera/Byannli for schizophrenia, and Ampyra for improving walking in patients with multiple sclerosis.

Alkermes Plc is headquartered in Dublin, Ireland, and has a significant operational presence in the United States, including corporate offices and an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. The development and manufacturing business in Athlone, Ireland, was sold on May 1, 2024.

Alkermes Plc has been recognized as a "Great Place to Work" in the United States in 2024 and 2025, and has received accolades from Fortune Magazine and the Boston Globe. No specific negative events or controversies significantly impacting Alkermes Plc's public brand reputation in the past year were identified. Competitive pressures and dependence on key products are potential threats and weaknesses that could indirectly affect reputation if not managed effectively.

Alkermes Plc is primarily an institutionally-controlled company. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Baker Bros. Advisors Lp, State Street Corp, and Price T Rowe Associates Inc. Institutional shareholders hold 108.19% of Alkermes stock, while insiders hold 7.50%, and retail investors hold 0.00%. Elan Corp PLC is the largest individual shareholder, owning 4.65% of the company.